Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment

BACKGROUND: Immune checkpoint blockade (ICB) therapy holds promise in metastatic urothelial carcinoma (UC). Fibroblast growth factor receptor 3 (FGFR3) mutation drives T-cell-depleted microenvironment in UC, which led to the hypothesis that FGFR3 mutation might attenuate response to ICB in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yuxuan, Peng, Yun, Qin, Caipeng, Wang, Yulong, Yang, Wenbo, Du, Yiqing, Xu, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546120/
https://www.ncbi.nlm.nih.gov/pubmed/37777251
http://dx.doi.org/10.1136/jitc-2022-006643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546120/
https://www.ncbi.nlm.nih.gov/pubmed/37777251
http://dx.doi.org/10.1136/jitc-2022-006643

Ejemplares similares